What You Should Know:
– Distalmotion, a MedTech company with a mission to empower access to the benefits of robotic surgery secures $150M in Series G financing round led by Revival Healthcare Capital.
– The new funding will primarily be used to accelerate the U.S. commercial adoption of its soft tissue robotic surgery system, DEXTER. A major focus of the U.S. expansion is the Ambulatory Surgery Center (ASC) market, recognized as one of the fastest-growing segments in surgical care due to the ongoing shift toward efficient, outpatient surgery.
DEXTER®: Designed for Flexibility and Outpatient Sites
The DEXTER® Robotic Surgery System is designed to simplify operations, making the benefits of wristed robotics accessible in any operating room (OR), especially the smaller footprints of ASCs.
DEXTER’s unique features include:
- Mobility and Integration: A small, mobile footprint allows the robot to integrate into any size OR without modifications and be easily maneuvered between rooms.
- Flexible Workflow: The sterile console supports flexible surgical workflows by positioning the surgeon close to the patient for quick bedside access and seamless transitions between laparoscopic and robotic techniques.
- Open Architecture: Enables compatibility with existing and future OR technologies, including visualization systems and advanced devices, supporting cost-effective supply chain operations.
The system already has strong clinical traction with almost 3,000 patients treated across Europe and the U.S.
Chas McKhann Appointed As Executive Chariman
In conjunction with the financing, Distalmotion named Chas McKhann as Executive Chairman of the Board of Directors. Mr. McKhann brings over 25 years of MedTech and life sciences experience, including successful leadership roles as CEO of Apollo Endosurgery and Silk Road Medical.
